Clinical Studies

A new veterinary device composed of collagen and elastin particles has been developed; it has been shown to help protect cartilage from mechanical grinding. Previous anecdotal use of this product has been beneficial in dogs with elbow dysplasia.

Development of a safe and beneficial immunotherapy option for canine urothelial carcinoma patients will advance veterinarians' ability to treat this disease and will provide an important model to inform future canine and human clinical trials in this area.

Current chemotherapy treatments involve a direct injection into the tumor. We would like to use surgically removed lung tissue to better understand how drugs behave when they are injected into lung tumors in dogs, as well as humans, with lung tumors.

This study seeks to define the rate at which methylnaltrexone (MNTX) is metabolized in dogs following intravenous administration. Postoperative regurgitation is a common side effect of general anesthesia. The opioid-inhibiting effects of MNTX block the risk of opioid-related complications, without reducing pain control and pain management.

Xylitol is an artificial sweetener commonly found in sugar-free gum. Although safe for humans, xylitol is highly toxic to dogs. This study will compare the liver protective capacity of two veterinary liver protectant products in dogs suffering from xylitol toxicity.

Immune-mediated thrombocytopenia (ITP) is a disorder characterized by severely low platelets due to attack by white blood cells. This is often associated with bruising and occasionally severe bleeding episodes.

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

The intestinal microbiota are highly functional, with a combined genome (termed the microbiome) that is approximately 130-160 times larger than the human or canine genome. The microbiome is a highly functional organ and produces approximately 1,000 different metabolites, many of which have systemic effects in the dog.

Despite years of active research in the field, high mortality rates associated with sepsis have remained unchanged over the last three decades; we aim to change this!

Following removal of the primary tumor and adjuvant chemotherapy, the development of lung metastasis is the most common cause of mortality in dogs with osteosarcoma. A distinctive feature of lung metastases of osteosarcoma in human patients is the surprising benefit that can result from surgical resection of the lung nodules. The use of surgery to

Naturally occurring cancers in dogs have been as used as models for human cancers for many reasons; however, the genomic profiles of many of these cancers are still incompletely understood. Further definition of these genomic landscapes will allow for improved development of novel diagnostics and therapeutics to diagnose and treat these cancers. The objective of this

Research Type Ethos Discovery De Novo Study Description Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second